Health-care companies were more or less flat as traders awaited more updates on obesity drugs.

Medical meetings such as the coming weekend's gathering of the American Diabetes Association are increasingly dominated by news on obesity drugs from Eli Lilly, Novo Nordisk, Zealand Pharma, Altimmune, and others.

Write to Rob Curran at

(END) Dow Jones Newswires

06-17-24 1701ET